Benzinga | Nov 4, 2021 09:41AM EDT

Lantern Pharma Announces Abstract On Effectiveness Of LP-284 In Hematologic Cancers Accepted For Presentation At The 63rd American Society Of Hematology Annual Meeting

Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR(r) artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-284 in hematologic cancers has been accepted as a poster at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, which is being held in-person and virtually from December 11 -- 14, 2021. The abstract is available online on the ASH website.



Abstract Title The Positive Enantiomer of a Novel Chiral DNA Alkylating Agent Exhibits Nanomolar Potency in Hematologic Cancers

Session Name 802. Chemical Biology and Experimental Therapeutics: Poster III

Abstract Number 3991

Poster Session Date & Time Monday, December 13, 2021, 6:00 PM - 8:00 PM

Presenter Jianli Zhou, Ph.D., Lantern Pharma